<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/18/crispr-therapeutics-nasdaqcrsp-hits-new-1-year-high-at-57-77.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-18T12:38:12+00:00"/>
    <meta property="og:title" content="Crispr Therapeutics (NASDAQ:CRSP) Hits New 1-Year High at $57.77"/>
    <meta property="og:description" content="Shares of Crispr Therapeutics AG (NASDAQ:CRSP) hit a new 52-week high on Monday . The stock traded as high as $57.77 and last traded at $57.00, with a volume of 25559 shares changing hands. The stock had previously closed at $56.87. Several brokerages recently weighed in on CRSP. Chardan Capital set a $72.50 target price […]"/>
  </head>
  <body>
    <article>
      <h1>Crispr Therapeutics (NASDAQ:CRSP) Hits New 1-Year High at $57.77</h1>
      <address><time datetime="2019-11-18T12:38:12+00:00">18 Nov 2019, 12:38</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/crispr-therapeutics-ag-common-shares-logo.png"/>
      </figure>
      <p>Shares of Crispr Therapeutics AG (NASDAQ:CRSP) hit a new 52-week high on Monday . The stock traded as high as $57.77 and last traded at $57.00, with a volume of 25559 shares changing hands. The stock had previously closed at $56.87.</p>
      <p>Several brokerages recently weighed in on CRSP. Chardan Capital set a $72.50 target price on Crispr Therapeutics and gave the company a “buy” rating in a report on Monday, October 21st. Canaccord Genuity started coverage on Crispr Therapeutics in a research report on Friday, July 26th. They set a “buy” rating and a $72.00 price target for the company. Oppenheimer raised Crispr Therapeutics from a “market perform” rating to an “outperform” rating and set a $65.00 price target for the company in a research report on Tuesday, November 12th. Barclays upped their price target on Crispr Therapeutics from $59.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Finally, Needham &amp; Company LLC reaffirmed a “buy” rating and set a $62.00 price target on shares of Crispr Therapeutics in a research report on Wednesday, July 31st. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $57.95.</p>
      <p>The stock has a market cap of $3.04 billion, a P/E ratio of -16.86 and a beta of 3.15. The firm has a 50-day moving average price of $43.31 and a 200-day moving average price of $44.57. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.</p>
      <p>Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. On average, research analysts predict that Crispr Therapeutics AG will post 0.64 earnings per share for the current year.</p>
      <p>In related news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The transaction was disclosed in a filing with the SEC, which can be accessed through <a href="https://www.sec.gov/Archives/edgar/data/1205703/000120919119056372/xslF345X03/doc4.xml">this link</a>. 21.40% of the stock is owned by company insiders.</p>
      <p>A number of hedge funds have recently bought and sold shares of CRSP. Xact Kapitalforvaltning AB bought a new position in Crispr Therapeutics during the 2nd quarter valued at approximately $207,000. Commonwealth Equity Services LLC boosted its stake in shares of Crispr Therapeutics by 5.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock worth $839,000 after buying an additional 986 shares during the last quarter. Buckley Wealth Management LLC purchased a new position in shares of Crispr Therapeutics in the 2nd quarter worth $236,000. Carnegie Capital Asset Management LLC purchased a new position in shares of Crispr Therapeutics in the 2nd quarter worth $1,064,000. Finally, Moody Aldrich Partners LLC purchased a new position in shares of Crispr Therapeutics in the 2nd quarter worth $1,838,000. 50.50% of the stock is owned by institutional investors.</p>
      <p><b>Crispr Therapeutics Company Profile</b> (<a href="https://www.marketbeat.com/stocks/NASDAQ/CRSP/">NASDAQ:CRSP</a>)</p>
      <p>CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.</p>
      <p>Further Reading: <a href="https://www.marketbeat.com/financial-terms/what-is-quick-ratio/">What is the Quick Ratio?</a></p>
    </article>
  </body>
</html>